ArticleJournal of thoracic disease2025
Non-massive versus massive hemoptysis and the impact of preoperative embolization in patients with destroyed lung parenchyma: a single-center experience.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pulmonary architectural destruction often leads to significant clinical manifestations, including productive cough, recurrent infections, and hemoptysis, which may range from mild to life-threatening. This study aimed to compare perioperative outcomes between patients with non-massive and massive hemoptysis undergoing surgical resection for hemoptysis secondary to inflammatory/infectious lung diseases with pulmonary parenchymal destruction and to evaluate the impact of preoperative bronchial artery embolization (BAE) in those with massive hemoptysis. Methods: A retrospective analysis was conducted on patients treated between 2019 and 2024. Patients were categorized into two groups based on hemoptysis severity. A subgroup analysis was performed among those with massive hemoptysis, comparing outcomes between patients who underwent preoperative BAE and those who did not. All patients were followed up for 1 year. Exclusion criteria included incomplete records and loss to follow-up. Results: Fifty-one patients were included (mean age 42 years, 57% female). Non-massive hemoptysis was observed in 32 patients: 19 presented with massive hemoptysis. Among the latter, 8 underwent preoperative BAE. Massive hemoptysis was associated with increased need for transfusion (P=0.046) and prolonged intensive care unit (ICU) stay (P=0.02). In the embolization subgroup, patients without BAE had significantly longer pleural drainage (P=0.01), greater intraoperative blood loss (P=0.050), longer ICU stay (P=0.02), and higher transfusion rates (P=0.03). Conclusions: Massive hemoptysis is associated with greater perioperative morbidity. Preoperative BAE appears to be a beneficial and safe adjunct, improving surgical outcomes by reducing bleeding, transfusion needs, and ICU length of stay.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.